Full text is available at the source.
Abstract
GLP-1 receptor agonists may be associated with reduced all-cause mortality and heart failure hospitalizations in patients with obesity and type 2 diabetes.
- Comparisons were made between GLP-1 receptor agonists, DPP4 inhibitors, and sulfonylureas.
- The evaluation focused on patients with obesity, type 2 diabetes, and heart failure with preserved ejection fraction.
- Results regarding mortality and heart failure hospitalizations were assessed.
Simplified